Looking for something specific?
At 9M India Limited, trust through quality, transparency, performance.
What We Manufacture
CNS tablets require exceptional content uniformity and batch-to-batch consistency — patients with epilepsy, depression and psychiatric conditions depend on precise, reliable dosing. Our WHO-GMP certified manufacturing processes deliver this consistency across the full CNS tablet range.
First and second-generation antiepileptic drugs for seizure control across all epilepsy types.
SSRI, SNRI and tricyclic antidepressants for depression, anxiety disorders and neuropathic pain.
First and second-generation antipsychotics for schizophrenia, bipolar disorder and related conditions.
Benzodiazepine and non-benzodiazepine anxiolytics for anxiety disorders, insomnia and procedural sedation.
Why 9M India
CNS tablets, particularly low-dose formulations like antiepileptics and antipsychotics, require validated blending, granulation and compression processes ensuring content uniformity within ±5% of label claim. 9M India uses controlled low-shear granulation, validated blend uniformity testing and in-process content uniformity checks at compression — meeting the tight specifications that neurological and psychiatric drug therapy requires.
Dissolution testing · Disintegration · Hardness · Friability · Assay (HPLC) · Content uniformity · Related substances · Microbiological limits — all tested in our in-house analytical laboratory. Certificate of Analysis issued from our own facility.
Manufacturing Licence · DCGI product approvals · WHO-GMP Certificate · COA · COC · Stability data (ICH aligned) — pre-prepared and available within 24 hours for tender submission, export registration or CDMO due diligence.
Who We Supply
Government & institutional buyers
Government mental health programmes, district hospitals, psychiatry and neurology departments — CNS drugs are a growing procurement priority as India's mental health burden is formally recognised and funded.
Domestic pharma brands (3PM/Private Label)
Domestic pharma brands manufacturing CNS tablets under private label — complete manufacturing capability from 0.25mg Alprazolam through to 1000mg Levetiracetam.
International export buyers
Middle Eastern and South-East Asian buyers — antiepileptic and antidepressant demand is rising consistently across all export markets as mental health conditions receive greater clinical recognition.
Share your molecule, strength and market. We confirm capability and documentation within 24 hours.
WHO-GMP
Certified Facility
In-House QC
Contract &
3PM Available
DCGI
Approved
Therapeutic Categories
Our tablet portfolio covers the therapeutic areas most demanded across domestic institutional supply, generic pharma distribution and international export programmes.